Melanie Simon-Giblin

As a dual-qualified lawyer in New York and Paris, Melanie handles complex cross-border financial transactions for tech, biotech and medtech companies.

Her experience includes a broad range of capital markets transactions on Euronext and Nasdaq, from equity – initial public offerings (IPOs), dual listings, capital increases, private placements, private investments in public equity (PIPEs), block sales, and at-the-market (ATM) offerings – to debt, including high-yield and convertible bonds.

Before joining Cooley, Melanie worked in the New York office of a Paris-based international law firm.

Melanie’s representative matters include advising:

• Inventiva on a multitranche equity financing of up to 348 million euros*
• The underwriters on Abivax’s $235.8 million IPO – the largest-ever US IPO of a French-listed biotechnology company*
• The underwriters on Valneva’s 102.9 million euros capital increase*
• A bank syndicate on DBV Technologies’ $194 million PIPE deal*
• Talend on its acquisition by Thoma Bravo for $2.4 billion*

*Matters handled before joining Cooley